Pacific Biosciences of California, Inc. — Blitz Index 29 (D)
Pacific Biosciences scores 29 — long-read sequencing's pioneer, held back by a $641M convertible wall, a third straight guidance cut, and a CFO resignation weeks before the print.
Last re-scored: November 4, 2026.
Confidence: Medium · Category: frontier
Score breakdown
| Section | Score | Detail |
|---|---|---|
| A · Speed | 9 / 25 | Q3 revenue +5.7% YoY after a −1.9% Q2, but consumables turned YoY-negative (−2.4%) and FY2026 guidance was cut for the third time, to $155–160M |
| B · Moat | 23 / 60 | HiFi accuracy and a razor/blade installed base (Revio 381, Vega 235) with SPRQ-Nx on most consumables — but no platform lock-in, and ONT contests the same ceiling |
| C · Creative destruction | 9 / 15 | Long-read displacing short-read in structural variants and rare disease — real but narrow, with short-read still the volume standard |
| D · BlitzFailing | −12 | Convertibles $641M, ~4.0× TTM revenue, cash down $37.5M in the quarter to $199.4M (D1 −6); guidance cuts and a CFO resignation (D2 −3); SB Northstar covenants (D3 −1); weak research funding (D4 −2) |
Think we scored it wrong? Score it yourself →
Radar axes (0–100): Moat 38.3 · Speed 36.0 · Creative 60.0.
Watch item
Gates: G1 ✓ (confirmed, borderline — repeat consumable purchase and installed-base growth, though consumables turned YoY-negative) · G2 ✓ (estimated — long-read only; the narrowest 2030 vendor estimate, $3.74B, is 2.3× the $1.61B bar). 36 points below the 65-point threshold — a Q3 2026 rescore of the unpublished draft (30/D → 29/D, D2 −2 → −3). No FLAG: deductions of 12, three points of headroom. Watch: Q4 guidance, cash guidance, and whether the 2029 convertible maturity forces a refinancing before the 2028 cash-flow breakeven target.
Strengths
- Revenue turned positive: Q3 +5.7% YoY (Q2 −1.9%), instruments +16.8% and services +13.8%
- Vega rebound: 35 instruments installed (+9% YoY, over 90% new customers), after a soft Q2
- SPRQ-Nx adoption is real: most of Revio consumable revenue and two-thirds of the installed base upgraded — the $345/genome cost-curve argument with adoption evidence
- Revio installs grew YoY (13 → 15) — the draft's G1 re-examination tripwire did not trigger
- Non-GAAP operating expenses −13% YoY — restructuring savings are showing
Concerns
- Consumables turned YoY-negative (−2.4%): the core repeat-purchase metric bent, and pull-through fell to ~$204k from ~$236k
- Guidance cut a third time: FY2026 $155–160M (top −$5M), eroding guidance credibility
- Cash fell $37.5M in the quarter to $199.4M; net debt is ~$442M and widening
- CFO resigned on 2026-11-03, days before the print — the financial reporting chief changed hands
- Margins keep shrinking YoY: GAAP 33% (from 41%), non-GAAP 36% (from 42%)
Research notes
Thesis: the gates pass, the business stalls
Pacific Biosciences enters the BlitzLab record with a rescore of 29 out of 100, grade D, built from Speed 9 out of 25, Moat 23 out of 60, Creative Destruction 9 out of 15, and deductions of 12. The total sits 36 points below the 65-point line, and the shape of the score is the story: creative destruction converts to 60.0 while speed converts to only 36.0 and the moat to 38.3. This is the long-read sequencing pioneer — trailing-twelve-month revenue of $161.4 million — whose third quarter turned revenue positive again (+5.7%) and whose Vega instrument rebounded, yet whose consumables, the repeat-purchase engine of the razor/blade model, turned YoY-negative, whose full-year guidance was cut for the third time, and whose chief financial officer resigned days before the print. The rescore moves one point from the unpublished draft (30/D → 29/D), and the single moving item is D2, widened from −2 to −3 on the guidance cut and the CFO resignation.
What the company does
Pacific Biosciences is the long-read sequencing pioneer, selling HiFi sequencing instruments — Revio and Vega — plus the consumables and services that go with them, a razor-and-blade model. The third quarter of 2026, reported on 2026-11-04, is a rescore: total revenue of $40.6 million, up 5.7% year on year after a 1.9% decline in the second quarter, with instruments up 16.8%, services up 13.8%, and consumables — the repeat-purchase engine — at $20.8 million, down 2.4% year on year. Revio installed 15 systems in the quarter, up from 13 a year earlier, for a cumulative 381; Vega installed 35, up from 32 a year earlier, for a cumulative 235. Revio pull-through was about $204,000, down from about $236,000 a year earlier. SPRQ-Nx, at $345 per genome, now accounts for more than half of Revio consumables revenue, and two-thirds of the installed base has chosen the upgrade. Trailing revenue is $161.4 million.
Headcount has shrunk with restructuring to about 445 after July 2026, from 575 at the end of 2024, so trailing revenue per employee is about $363,000 — a shrinking denominator rather than proven productivity. Gross margin was 33% on a GAAP basis, down 8 points from 41% a year earlier; non-GAAP was 36%, down 6 points from 42% a year earlier. Full-year 2026 revenue guidance was cut again, to $155–160 million — the third move down. Academic and government research funding weakness in the Americas and China is cited as a continuing demand headwind.
Why it scored what it did
Speed is 9 of 25, converting to 36.0, and the moat is 23 of 60, converting to 38.3 — both low, with only creative destruction at 9 of 15, or 60.0, holding the total up. Growth (A1, 3) credits the return to positive growth, but the consumables turn negative, the guidance cut is the third, and pull-through keeps falling, so the draft's 3 is unchanged. Capital speed (A2, 2) reflects a shrinking cash pile: $199.4 million, down $37.5 million in the quarter, with no new equity issuance in 2026. Hiring (A3, 2) is unchanged from the draft: headcount is falling and the revenue-per-employee rise is a denominator effect. Share speed (A4, 2) balances Revio installs up year on year and Vega rebounding against the pull-through decline and consumables turn.
The moat is 23 of 60 and its shape is defensive rather than expansive. Network effects (B1, 6) sit in the middle of the data-and-ecosystem band: the HiFi accuracy standard, the installed base and validated clinical workflows create switching costs — but Oxford Nanopore offers a direct substitute, so this is not platform lock-in. Distribution (B2, 7) is repeatable paid and partner distribution: global direct sales and distributors, an installed base that pre-sells consumables, and the Verily, TychoBio and population-scale wins — but instrument demand is tied to research budgets, and Vega installs swing quarter to quarter. Market size (B3, 7) passes on the narrow long-read definition alone: $3.74 billion by 2030 on the lowest vendor estimate, 2.3 times the bar of $1.61 billion — held at 7 because it is a single vertical and share is contested with Oxford Nanopore. Gross margin (B4, 3) is low and shrinking year on year. Creative destruction is 9 of 15: long-read replaces short-read for hard variants, but short-read remains the volume standard and the $345-per-genome cost step has not yet connected to a pull-through recovery.
The risks
Deductions total 12, three points below the 15-point FLAG line, and half of them sit in a single item. Debt (D1, −6) is the convertible wall: principal of $641 million, about 4.0 times trailing revenue, with the third-quarter balance unconfirmed (10-Q not cross-checked); cash of $199.4 million leaves net debt of about $442 million, widening from about $404 million in the draft; maturities fall in 2029 ($200 million) and 2030 ($441 million) at coupons of 1.375–1.5%, low enough to keep the deduction short of the maximum. The 2029 maturity arrives before the company's own 2028 cash-flow breakeven target. Revenue quality (D2, −3) is the one item that moved in the rescore, widened from −2: the third guidance cut, and chief financial officer Jim Gibson's resignation on 2026-11-03, days before the print. No restatement or auditor-opinion issue is confirmed. Governance (D3, −1) records no dual-class concentration, but SB Northstar creditor influence constrains financial freedom. Regulation (D4, −2) is the demand headwind itself, with no realised fine, sanction or product-safety event.
What would change the score
The rescore moved one point from the unpublished draft, 30/D to 29/D, on D2 alone. Consumables returning to positive year-on-year growth and pull-through recovering from about $204,000 would repair the repeat-purchase engine; meeting the $155–160 million full-year guidance would restore the credibility the third cut damaged; and a successor chief financial officer would close the reporting-risk item opened on 2026-11-03. The structural question is longer: the $641 million wall matures in 2029, before the 2028 breakeven target.
The gates: both pass — the second only as an estimate
Gate 1, two pieces of product-market-fit evidence for a growth company, passes on a confirmed basis, but at the borderline. Repeat purchase holds on consumables of $20.8 million in the quarter, and installed-base growth holds on Revio installs rising year on year (13 → 15) with Vega rebounding (32 → 35) — though the draft's re-examination tripwire (consumables YoY-negative AND Revio installs down two quarters running) was only half-tripped. Gate 2, a ten-year market ceiling at least ten times current revenue, passes as an estimate on the narrow long-read definition only: the bar is $1.61 billion, ten times trailing revenue, and the lowest 2030 vendor estimate of $3.74 billion clears it 2.3 times. The fourth quarter of 2026 has not been reported at T, and its reporting date is unconfirmed — it is not a company-confirmed date and must not be presented as one — and no outcome is anticipated here. That is the balance of the record at T: a substitution thesis that survives, a business that does not accelerate, and a $641 million convertible wall maturing in 2029, before the company's own 2028 cash-flow breakeven target.
More Frontier companies
Other Frontier names on the Blitz Index, highest score first: Rocket Lab (62/B), Tesla (62/B), Illumina, Inc. (61/B).
Next earnings
Q4 2026 · Expected
Coverage
Pacific Biosciences of California, Inc. · Next earnings unconfirmed at scoring · Score 29 · Grade D
Embed this score
Copy the HTML below to show this score on your site. The badge links back to this page and updates automatically when the score changes.
Preview:
BlitzLab scores businesses against a scholar’s standard — not investment advice. No price targets, no buy/sell recommendations. Figures are from SEC filings (XBRL) as labeled in the source scorecard.